Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.
David Hogan, Client Portfolio Manager for Laudus Mondrian's Emerging Markets Fund sees emerging Asian markets as well positioned for the economic recovery.